SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Beta-FeOOH particles were synthesized in the presence of Ti(IV), Al(III), and Cr(III) at metal/Fe atomic ratios of 0-0.1 by the following two methods: hydrolysis of aqueous FeCl3 solutions added to the hydrolysis products of these metal ions (subsequent hydrolysis, SH) and hydrolysis of aqueous FeCl3 solutions dissolving these metal ions (combined hydrolysis, CH). On increasing Al/Fe the particle size of the products with AlCl3 by SH method steeply rose at a low Al/Fe and then fell. The similar increase of particle size was seen in SH method with Ti(SO4)2 though the addition of TiCl4 decreased the particle size. In CH method, Ti(IV) markedly impeded the beta-FeOOH formation but Al(III) and Cr(III) showed no influence. The particles prepared by CH and SH methods contained a large amount of Ti(IV) but a few Al(III) and Cr(III). The large spindle-shaped and rod-shaped particles produced by SH method with AlCl3 and Ti(SO4)2 were highly microporous and poorly crystallized, indicating that the particles consist of fine primary particles and the aggregation of fine particles would be promoted by SO4(2-). The different influences of the metal ions on the beta-FeOOH formation were explained by their hydrolysis characteristics.
Due to their favourable properties such as high dose localization and high RBE heavy-ion beams have attracted increasing interest in cancer treatment. Efforts to exploit these advantages to the maximum extent in cancer therapy have never been given up. A new idea of applying a radioactive ion beam with beta-delayed particle decay such as 9C or 8B to cancer therapy is put forward in this paper. A model to evaluate the biological effect in terms of cell survival induced by the emitted particles from the decays of the stopped ions has been established. Because of the difference of the internally emitted particle irradiation from the external ion beam, the microdosimetric quantity such as specific energy is applied to evaluate the cell surviving effect induced by the emitted particles from the decays of the radioactive ions. Within the framework of this model, the cell-killing effects resulting from the emitted particles were calculated under different conditions. Finally, the potential application of the radioactive ion beam 9C in cancer therapy is demonstrated.
(1-->3)-beta-D-Glucans remained in the liver and spleen for long time, i.e. more than a month, without major structural changes/because there is no specific metabolic pathway for it in the body. However, biological activities, such as priming activity to LPS, triggered TNF-alpha synthesis, and antitumor activity was reduced more quickly. In this paper, we demonstrated the contribution of protein binding in inactivating beta-glucans. A particle beta-glucan preparation, zymosan, was treated with serum or plasma at 37 degrees C and their various biological activities were compared with zymosan alone. Such biological activities as antitumor activity, TNF-production, IL-6 production, complement activation and vascular permeability were significantly decreased by serum or plasma treatment. These results strongly suggested that the binding of serum or plasma protein(s) to beta-glucans would be a key step in inactivating a particle beta-glucan in the body.
A mathematical model of the process of collecting and analyzing a grab sample of radon decay products in air can be useful for a number ofpurposes. Among them is predicting the observed counts of alpha particles and/or beta particles (1) under various conditions of radon decay product equilibrium; (2) for various sampling, delay and counting times; and (3) for various counting efficiencies for the particles emitted by the collected decay products.
The phagocytosis of beta-glucan particles by human neutrophils and the associated activation of NADPH O2- forming oxidase were accompanied by an increased hydrolysis of phosphoinositides by phospholipase C, hydrolysis of phosphatidylcholine by phospholipase D, accumulation of diglyceride (DG) mass, and [Ca2+]i rise. The reaction of phospholipid hydrolysis played a minor role in the formation of DG, which was mainly formed by de novo synthesis from glucose. The activation of this pathway was shown by the stimulation of the incorporation of [U-14C]glucose into DG, which occurred very rapidly after the challenge of neutrophils with beta-glucan particles. This DG derived from glucose was found almost completely as 1-acyl-2-acyl-glycerol (DAG). On the basis of the finding that phosphatidic acid was the precursor of DAG, an increase in the incorporation of [U-14C]acetate into DAG did not occur, and the [14C]radioactivity was in the glycerol backbone, the synthesis of DAG from [U-14C]glucose occurred very likely via dihydroxyacetone phosphate and glycerol 3-phosphate, stepwise acylation to phosphatidic acid, and dephosphorylation by phosphatidate phosphatase.
A radioactive ion beam like 9C serves as a double radiation source and may be useful in cancer treatment, where the essential irradiation comes from the external beam itself and the extra one is due to the low-energy particles emitted internally during the decay of 9C. Based on the microdosimetric specific energy spectrum in cell nuclei, a model to evaluate the biological effect induced by the internally emitted particles from a beta-delayed particle decay beam has been developed. In this paper, using this model the additional contributions to the cell-killing effect due to the emitted particles from stopping 9C ions were incorporated in the design of spread-out Bragg peaks (SOBP) for radioactive 9C beams. For this purpose, a simulated annealing algorithm was employed to optimize the superposing weighting fractions of all monoenergetic beams so that a uniform cell survival level could be realized across the SOBP within an acceptable deviation of 5%. SOBPs with different widths and at different cell survival levels were designed for both therapeutic 9C and 12C beams for comparison. The potential use of the 9C beam in radiotherapy compared to the 12C beam, which is commonly adopted in the practices of current heavy-ion therapy, is shown systematically in terms of the distributions of biological effective dose and cell survival along the beam penetration.
Beta-tricalcium phosphate (beta-TCP) has been encapsulated with poly(ethylene glycol) (PEG) to improve the filler/cement interface, and it was later incorporated to a poly(methyl methacrylate) bone cement in order to obtain cements with improved stability in the long term. Size and size distribution of the agglomerates forming the initial powder was drastically changed after its dispersion in a PEG aqueous solution. Whereas the initial beta-TCP particles had a 584 microm average diameter, the treated particles (TCP-PEG) presented more than 60% of the particles in a range of 2-6 microm. The effect of adding the treated particles to an acrylic cement was evaluated in terms of curing parameters, in vitro behaviour and mechanical performance. The presence of the TCP-PEG particles did not affect either peak temperature or setting time, indicating a good homogeneity of polymerising mass in contrast to the effect observed with the plain beta-TCP particles, which gave rise to higher setting times. In vitro behaviour studies revealed hydration degree values of the modified cements comparable to that of PMMA cements. Early stages of water uptake was Fickian in nature for all the experimental formulations indicating that the water absorption followed a diffusion controlled mechanism. After 3 months of storage in SBF the experimental formulations presented values of compressive strength in the range 76-78 MPa, higher than the minimum required by ISO 5833 (70 MPa) and those of tensile strength in the range 42-48 MPa, higher than the minimum reported for commercial formulations (30 MPa), but no significant differences in the strengths and elastic modulus were observed with the treatment of the filler particles. This observation was confirmed by ESEM analysis of the tensile fracture surfaces, which revealed a rather good cohesion between the bioceramic particles with some gaps around them, independently of the type of particles. The themogravimetric analysis of dry and wet specimens showed a higher dissolution rate of the plain beta-TCP particles in comparison to the encapsulated ones, indicating that the PEG adsorbed on the surface of the TCP particles could be a way to control the resorbability of the bioceramic component.
The Food and Drug Administration (FDA) is amending its bottled water quality standard regulations by establishing an allowable level for the contaminant uranium. As a consequence, bottled water manufacturers are required to monitor their finished bottled water products for uranium at least once each year under the current good manufacturing practice (CGMP) regulations for bottled water. Bottled water manufacturers are also required to monitor their source water for uranium as often as necessary, but at least once every 4 years unless they meet the criteria for the source water monitoring exemptions under the CGMP regulations. FDA will retain the existing allowable levels for combined radium-226/-228, gross alpha particle radioactivity, and beta particle and photon radioactivity. This direct final rule will ensure that the minimum quality of bottled water, as affected by uranium, combined radium-226/-228, gross alpha particle radioactivity, and beta particle and photon radioactivity, remains comparable with the quality of public drinking water that meets the Environmental Protection Agency's (EPA's) standards. FDA is issuing a direct final rule for this action because the agency expects that there will be no significant adverse comment on this rule. Elsewhere in this issue of the Federal Register, FDA is publishing a companion proposed, rule under the agency's usual procedure for notice-and-comment rulemaking, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule. The companion proposed rule and direct final rule are substantively identical.
In developing and designing radioimmunotherapy, the selection of the isotope is a major factor. This selection depends on a number of criteria and parameters, affecting usefulness and feasibility. Usefulness is directly related to the radiological performance of the ionising radiation in relation to tissue and its morphology, with a major distinction between the effects of alpha and beta-particles (or rays). Usefulness is also directly related to the pharmacodynamic performance of the isotope-carrier (e.g. antibody) complex, where the proper choice of isotope radiodecay halflife is of major importance. Feasibility depends on availability of the components in the isotope-ligand-carrier complex, and also on convenience and safety aspects in the preparation and the handling of the materials as well as in their application in patients. A comparison is made between the various properties of alpha-emitting isotopes that have been proposed over a number of years, concluding that the combination 225Ac- 213Bi deserves serious further attention.
beta-FeOOH particles were prepared by aging aqueous FeCl3 solutions containing Ti(IV), Cr(III), and Cu(II) at room temperature for 360 days. The structures of the formed particles were investigated by various techniques including TEM, XRD, XAFS, and adsorption of N2 and H2O. Ti(IV) markedly impeded the crystallization and particle growth of beta-FeOOH by coprecipitation with Fe(III) and disturbing the short-range structure of beta-FeOOH particles. In the presence of a large amount of Ti(IV), it was pronounced that the hydrolysis of Ti(IV) impeded beta-FeOOH formation by reducing the solution pH, whereas Cr(III) and Cu(II), which were hardly involved in the products, gave rise to no noticeable effects on the formation of beta-FeOOH particles. The knowledge obtained in this study can be available for interpretation of the anti-corroding function of Ti alloyed with steels in a Cl- -containing environment.
Temporal and spatial patterns of osteoblast activation around beta-TCP particles implanted into bone were analyzed by in situ hybridization with digoxygenin-labeled procollagen alpha 1(I) RNA probes. beta-TCP particles (150-300 microns in diameter) were implanted into rat tibiae, and specimens were collected 3, 5, 7, 14, and 28 days after operation. Activated osteoblasts displayed intense procollagen alpha 1(I) RNA specific labeling. At day 3, osteoblasts lining pre-existing trabeculae in places showed a specific signal. Additionally, scattered activated cells compatible with preosteoblasts also were observed in the vicinity of the trabeculae among red blood cells that filled the space between beta-TCP particles. Osteoblast activation on the surface of beta-TCP rarely was observed. At days 5 and 7, osteoblast activation and bone formation advanced centripetally. At the forefront of bone formation positive cells were scattered in the blood cell clots, and some of the positive cells colonized forming new bone matrix. Formation of new bone did not always begin at the surface of beta-TCP. At day 14, most of the beta-TCP particles were tightly associated with newly formed bone, and the number of positive osteoblasts was reduced. At day 28, absorption of the newly formed bone and the beta-TCP by multinuclear cells was sporadically demonstrated. Such cells often were accompanied by active osteoblasts, suggesting early bone remodeling. In conclusion, in situ hybridization with procollagen alpha 1(I) was employed to demonstrate precisely the mode of recruitment of bone cell precursors. beta-TCP does not positively guide collagen I expressing bone cells along its surface. It has no apparent effects on bone regeneration.
OBJECTIVE: Lutetium oxyorthosilicate (LSO) contains natural radioactivity that emits beta particles and three gamma photons simultaneously. These beta particles and gamma photons increase the single and random rates in a positron emission tomography (PET) system while a beta particle and gamma photon produced in the same decay of Lu-176 and detected by another detector can be beta-gamma coincidence true events. The purpose of this work is to measure the single, random, and true count rates due to the natural radioactivity in LSO and determine the optimum lower energy threshold level for an energy window in an LSO-based clinical PET. METHODS: First, we measured the energy spectra of these beta particles and gamma photons in LSO using a single crystal to obtain the basic data. Then, we measured single, random, and true count rates of an LSO-based clinical PET from the natural radioactivity as a function of the lower energy threshold. RESULTS: In the PET, single and random count rates due to the natural background activity were gradually decreased as the lower energy threshold level increased. The true count rates due to the beta-gamma coincidence were more than 10 kcps below a lower energy threshold of 250 keV. However, these true count rates due to the natural radioactivity in LSO can be decreased to less than 1 kcps at a lower energy threshold level set at more than 350 keV. CONCLUSION: With these considerations, in an LSO-based clinical PET, a lower energy threshold level set at above 350 keV is recommended.
This paper describes Q beta noninfectious particles produced at 41 degrees C in a streptomycin-resistant Escherichia coli mutant which is temperature sensitive for suppression of a nonsense codon. The noninfectious particles resembled Q beta under the electron microscope and contained coat protein molecules in an amount similar to the amount in Q beta. However, they did not adsorb to F-piliated bacteria, and they were deficient in both minor capsid proteins of Q beta, maturation (IIa) and read-through (IIb). Proteins IIa and IIb were not produced in Qbeta-infected mutant cells at 41 degrees C. In addition, instead of the 30S RNA of Q beta, a shorter RNA, which sedimented mainly at 23 S, was found in the defective particles. The results are discussed in relation to the roles of proteins IIa and IIb of Q beta.
Although encouraging results have been obtained using systemic radioimmunotherapy in the treatment of cancer, it is likely that regional applications may prove more effective. One such strategy is the treatment of central nervous system leukemia in children by intrathecal instillation of targeting or nontargeting beta particle emitting radionuclide carriers. The beta particle dosimetry of the spine is assessed, assuming that the spinal cord and the cerebrospinal fluid compartment can be adequately represented by a cylindrical annulus. The radionuclides investigated were 90Y, 131I, 67Cu, and 199Au. It is shown that the radiation dose to the cord can be significantly reduced using short range beta particle emitters and that there is little advantage in using targeting carriers with these radionuclides. 199Au and 67Cu also have the advantage of having a suitable gamma emission for imaging, permitting pretherapy imaging and dosimetric calculations to be undertaken prior to therapy. If these methods prove successful, it may be possible to replace the external beam component used in the treatment of central nervous system leukemia in children by intrathecal radionuclide therapy, thus reducing or avoiding side effects such as growth and intellectual impairment.
Tissue response around beta-tricalcium phosphate (beta-TCP) particles (150-300 microm in diameter) implanted into rat tibiae was analyzed by in situ hybridization with digoxigenin-labeled procollagen alpha1(I) (COL), osteonectin, osteocalcin, and osteopontin (OPN) RNA probes. Specimens were collected at 3, 5, 7, and 10 days after the operation. Holes without implantation were used as control. In both the beta-TCP implanted and control groups, new bone was formed centripetally and all four kinds of mRNA were expressed in activated osteoblasts. A COL signal was expressed most strongly and widely, and was detected at the peripheral region of the hole at day 3. The other three mRNAs were also expressed in bone forming osteoblasts by day 7. However, in the earlier cell reaction stage, OPN expression in the beta-TCP implanted group was different than that in the control group: OPN mRNA was seen exclusively in the cells on the particles, and an OPN signal was detected not only in COL-positive cells, but also in COL-negative cells. The former cells may be osteoblasts and reflect the early process of bone formation on biomaterials. The latter cells may be macrophages and reflect foreign body reactions. Expression of these OPN mRNAs induced by implantation of beta-TCP may play a role in bone formation on the materials and in determining their biocompatibility.
Several radionuclides are being studied for use in radioimmunotherapy. Although 131I has been used most widely, there are several disadvantages to it including its large gamma-ray component, its rather long half-life, and its modest beta-particle energy. However, the beta-particle energy can be an advantage in very small tumors (less than 1-2 mm). 186Re has several potential advantages over 131I but it has never been directly compared with it experimentally. Dosimetry modeling predicted that 186Re would have a dose advantage over 131I at large tumor sizes but for tumors as small as 1 mm diameter, this advantage would be lost. In order to confirm these predictions experimentally, this study compared the relative efficacy of a pancarcinoma antibody, NR-LU-10 labeled with 186Re or 131I in 0.8-1.0 mm diameter LS174T human colon adenocarcinoma multicell spheroids. Spheroids were incubated for 90 hr at 37 degrees C and evaluated with clonogenic assay, autoradiography, and histology. When corrected for cumulative activity bound, both radionuclides were equally effective. Autoradiography demonstrated poor penetration of radionuclide into the depths of the spheroids. Because 186Re has a theoretical dose advantage in larger tumors and because it has been shown to be equivalent to 131I in tumors as small as 1 mm diameter, it may be superior to 131I in most clinical situations. However, in the treatment of micrometastases of less than 1 mm diameter, theoretical dosimetry modeling predicts that 131I or radionuclides with similar beta particle energies should be more effective.